Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Thu, 28.07.2022
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, July 28, 2022
Invitation to MorphoSys’ Second Quarter and First Half Year 2022 Results Conference Call on August 4, 2022
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half year 2022 results on August 3, 2022 at 10:00 pm CEST (9:00 pm BST; 4:0 [ … ]
Tue, 26.07.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 26, 2022
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)
Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 millio [ … ]
Tue, 26.07.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, July 26, 2022
MorphoSys Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million)
Update of financial guidance range for 2022 Monjuvi U.S. net product sales (now US$ 90 to US$ 110 millio [ … ]
Tue, 26.07.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, July 26, 2022
Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million [ … ]
Tue, 26.07.2022
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, July 26, 2022
Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
Preliminary Q2 2022 Monjuvi U.S. net product sales of US$ 23.3 million (€ 21.7 million [ … ]
Tue, 14.06.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, South San Francisco, United States, June 14, 2022
MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
Human Immunology Biosciences (HIBio) is a biotechnology company focused on developing precision medicines for autoimmune and inflammatory diseases, backed b [ … ]
Mon, 13.06.2022
MorphoSys AG
Media Release
New York, New York, U.S.; Boston, Massachusetts, U.S.; and Wilmington, Delaware, U.S., June 13, 2022
Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Pfizer Inc. (NASDAQ:PFE), MorphoSys U.S. Inc., a fully owned sub [ … ]
Fri, 10.06.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 10, 2022
MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib- [ … ]
Wed, 18.05.2022
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 18, 2022
MorphoSys AG Reports Outcome of Annual General Meeting 2022
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual General [ … ]
Thu, 12.05.2022
MorphoSys AG
Media Release
BOSTON, Mass., USA, May 12, 2022
MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
Efficacy and safety data from the ongoing Phase 2 MANIFEST study of pelabresib in myelofibrosis will be featur [ … ]